Latest Breaking News On - Alexandria forbes - Page 9 : comparemela.com

Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference

Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomBen ricklesMeiragtx holdingsAnnual genetic medicinesAlexandria forbesAnnual genetic medicines conferenceNext big thingVector gene therapyNon traditional vectors

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second

City ofUnited kingdomBen ricklesEmrys bio incMeiragtx holdingsJanssen pharmaceuticals incJanssen pharmaceutical companies of johnsonAlexandria forbesJanssen pharmaceuticalsJanssen pharmaceutical companiesUpcoming milestonesInvestigational new drugEmrys bioPrivate securities litigation reform actQuarterly reportThree month periods ended june

Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

Investegate announcements from MeiraGTx, MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

City ofUnited kingdomBen ricklesEmrys bio incMeiragtx holdingsJanssen pharmaceuticals incJanssen pharmaceutical companies of johnsonReports second quarterAlexandria forbesJanssen pharmaceuticalsJanssen pharmaceutical companiesUpcoming milestonesInvestigational new drugEmrys bioPrivate securities litigation reform actQuarterly report

Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx Reports First Quarter 2021 Financial and Operational Results

MeiraGTx Reports First Quarter 2021 Financial and Operational Results LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. “During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share in-vivo data later this year,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and

City ofUnited kingdomBen ricklesMeiragtx holdingsJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companies of johnsonClinical developmentReports first quarterAlexandria forbesJanssen pharmaceuticalsJanssen pharmaceutical companiesX linked retinitis pigmentosaRetinal dystrophyInduced xerostomiaInvestigational new drug

MeiraGTx Reports First Quarter 2021 Financial and Operational Results

MeiraGTx Reports First Quarter 2021 Financial and Operational Results LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share in-vivo data later this year, said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and

City ofUnited kingdomBen ricklesMeiragtx holdingsJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companies of johnsonClinical developmentAlexandria forbesJanssen pharmaceuticalsJanssen pharmaceutical companiesX linked retinitis pigmentosaRetinal dystrophyInduced xerostomiaInvestigational new drugGene regulation platform